Select Initial Public Offering Representations

• ArriVent BioPharma, Inc. in its $200 million initial public offering 
• Viela Bio, Inc. in its $172.5 million initial public offering
• Cowen and Company as lead underwriter in Praxis Precision Medicines, Inc.’s $218 million initial public offering
• G1 Therapeutics, Inc. in its $121 million initial public offering
• Sera Prognostics, Inc. in its $80 million initial public offering

Select Follow-on Offering and Alternate Transaction Representations 

• Viela Bio, Inc. in its $170 million follow-on offering 
• Goldman Sachs as lead underwriter in Fulcrum Therapeutics, Inc.’s $143 million follow-on offering and $75 million follow-on offering 
• Leerink Partners as lead underwriter in MoonLake Immunotherapeutics' $460 million follow-on offering
• Piper Sandler as lead underwriter in Praxis Precision Medicines, Inc.’s $172 million follow-on offering
• Aspen Aerogels, Inc. in its $275 million follow-on offering and its $75 million registered direct offering
• Aspen Aerogels, Inc. in a $100 million Convertible Note PIPE with an affiliate of Koch Strategic Platforms, LLC
• Synlogic, Inc. in multiple follow-on offerings raising aggregate proceeds of $180 million
• Aspen Aerogels, Inc. in $125 million common stock PIPEs with an affiliate of Koch Strategic Platforms, LLC 
• J.P. Morgan as lead underwriter in Acceleron Pharma Inc.’s $230 million follow-on offering 
• Cowen and Company as lead underwriter in Rocket Pharmaceuticals, Inc.’s $85 million follow-on offering
• Truist Securities as sole placement agent in Verastem Oncology, Inc.’s $60 million Series B Convertible Preferred Stock PIPE
• William Blair & Company as sole placement agent in Vapotherm, Inc.’s $23 million PIPE
• Leerink Partners as lead underwriter in ArQule, Inc.’s $65 million follow-on offering 

Select Mergers and Acquisitions Representations 

• Viela Bio, Inc. in its $3.05 billion sale to Horizon Therapeutics, Inc. 
• NET Power, Inc. in a business combination / de-SPAC to create a combined company valued at $1.5 billion 
• Elicio Therapeutics, Inc. in its reverse merger with Angion BioMedica Corp.
• Molecular Templates, Inc. in its reverse merger with Threshold Pharmaceuticals, Inc. 
• Synta Pharmaceuticals Corp. in its reverse merger with Madrigal Pharmaceuticals, Inc. 
• Seventh Generation, Inc. in its sale to Unilever 
• Presence Learning, Inc. in its acquisition of Global Therapy and a concurrent majority investment from Spectrum Equity, and The Rise Fund, TPG’s multi-sector global impact investment strategy